Cerebrospinal Fluid Leak Clinical Trial
Official title:
Post-market Clinical Data Collection Plan for the Biodesign® Dural and Duraplasty Grafts
NCT number | NCT04057157 |
Other study ID # | 17-10 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 3, 2019 |
Est. completion date | September 15, 2022 |
Verified date | October 2022 |
Source | Cook Group Incorporated |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this clinical study is to gather post-market clinical evidence on the use of the Biodesign® Dural and Duraplasty Grafts when used as a dura substitute of the dura mater.
Status | Completed |
Enrollment | 128 |
Est. completion date | September 15, 2022 |
Est. primary completion date | June 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Planned use of the Biodesign Dural or Duraplasty Graft. Exclusion Criteria: 1. Age <18 years 2. Unable or unwilling to provide informed consent 3. Life expectancy <6 months |
Country | Name | City | State |
---|---|---|---|
Canada | Toronto Western Hospital | Toronto | Ontario |
Italy | Ospedale Bellaria-Bolonga | Bologna | |
United States | University of Alabama Birmingham Hospital | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
Cook Research Incorporated |
United States, Canada, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients without clinically relevant cerebrospinal fluid (CSF) leakage | Clinically relevant CSF leakage is when it requires treatment (e.g., lumbar drain or surgical repair) or leads to an infection of the central nervous system (e.g., meningitis). | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02902133 -
Acetazolamide to Prevent Post Operative CSF Leak
|
Phase 2 | |
Recruiting |
NCT02927782 -
Mobilisation Algorithm After Incidental Durotomy
|
N/A | |
Completed |
NCT03566602 -
Evaluate the Safety and Performance of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
|
N/A | |
Completed |
NCT02891070 -
Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery
|
Phase 3 | |
Recruiting |
NCT04490629 -
The Efficacy and Safety of a Latest Dural Substitute
|
N/A | |
Withdrawn |
NCT04351061 -
Acetazolamide for the Prevention of Post Operative CSF Leak
|
Phase 2 | |
Recruiting |
NCT04086550 -
Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
|
N/A | |
Completed |
NCT02457546 -
The EVICEL® Neurosurgery Phase III Study
|
Phase 3 | |
Completed |
NCT04145544 -
A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes. To Evaluate the Safety and Effectiveness of ArtiFascia® in Subjects Requiring Dural Repair.
|
N/A | |
Completed |
NCT04124523 -
Perioperative CSF Leak Management - an Opinion Study
|
||
Active, not recruiting |
NCT04923867 -
Suturable DuraGen™ PMCF Study
|
||
Withdrawn |
NCT03181464 -
Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics
|
Phase 4 |